IVPost
Dr. J. William Charboneau receives lifetime achievement award
- Details
- Written by Ethan Grove
- Category: Medical News
For J. William Charboneau, M.D., life is a journey of unknown possibilities, filled with family. And Tuesday, November 28, with family both personal and professional by his side and in the audience, Dr. Charboneau's journey reached another destination.
Mayo Clinic develops neuro test that distinguishes demyelinating diseases from MS
- Details
- Written by Gina Chiri-Osmond
- Category: Latest News
Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder. Neurologic-related diseases commonly affect the brain, optic nerves and the spinal cord, and this new test can distinguish other IDDs such as neuromyelitis optica, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis from multiple sclerosis (MS).
Understanding and treating fibroelastomas
- Details
- Written by Dr. Kyle Klarich
- Category: Medical News
Fibroelastomas are formally known as papillary fibroelastomas, or PFEs, and are sometimes called cardiac papillomas. These small, noncancerous tumors develop in the heart - most often on one of the valves located between the heart chambers. Although they don't involve cancer, these tumors still pose a health threat, because they can increase your risk of developing blood clots that could lead to a heart attack or stroke. Treatment typically involves surgery to remove the tumor. If that's not possible due to other health considerations, then taking medication to lower the risk of blood clots is an option.
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
- Details
- Written by IVPost
- Category: Latest News
The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.
FDA Approval of a new formulation of buprenorphine
- Details
- Written by Commissioner Scott Gottlieb, M.D.
- Category: Latest News
With the approval today of a monthly formulation of the drug buprenorphine for the treatment of opioid use disorder, patients have access to a new and longer-acting option for the treatment of opioid addiction. Millions of Americans are suffering from addiction to opioid drugs, and millions more are worried that the overdose epidemic could claim the lives of a friend or loved one. We need immediate actions to help those suffering from an opioid use disorder transition to lives of sobriety.
FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder
- Details
- Written by IVP
- Category: Medical News
The U.S. Food and Drug Administration approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.
Page 35 of 50